spironolactone has been researched along with Alport Syndrome in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we explored the effects of SP on urinary protein excretion in patients with Alport syndrome featuring persistent proteinuria in spite of the long-term use of ACEI (lisinopril) or both ACEI and ARB (candesartan)." | 5.33 | The effect of aldosterone blockade in patients with Alport syndrome. ( Iijima, K; Kaito, H; Kanda, K; Matsuo, M; Nakanishi, K; Nozu, K; Przybyslaw Krol, R; Yoshikawa, N; Yoshiya, K, 2006) |
| " In this study, we explored the effects of SP on urinary protein excretion in patients with Alport syndrome featuring persistent proteinuria in spite of the long-term use of ACEI (lisinopril) or both ACEI and ARB (candesartan)." | 1.33 | The effect of aldosterone blockade in patients with Alport syndrome. ( Iijima, K; Kaito, H; Kanda, K; Matsuo, M; Nakanishi, K; Nozu, K; Przybyslaw Krol, R; Yoshikawa, N; Yoshiya, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giani, M | 1 |
| Mastrangelo, A | 1 |
| Villa, R | 1 |
| Turolo, S | 1 |
| Marra, G | 1 |
| Tirelli, AS | 1 |
| Hopfer, H | 1 |
| Edefonti, A | 1 |
| Crovetto, F | 1 |
| Moroni, G | 1 |
| Zaina, B | 1 |
| Acaia, B | 1 |
| Ossola, MW | 1 |
| Fedele, L | 1 |
| Kaito, H | 1 |
| Nozu, K | 1 |
| Iijima, K | 1 |
| Nakanishi, K | 1 |
| Yoshiya, K | 1 |
| Kanda, K | 1 |
| Przybyslaw Krol, R | 1 |
| Yoshikawa, N | 1 |
| Matsuo, M | 1 |
1 review available for spironolactone and Alport Syndrome
| Article | Year |
|---|---|
Pregnancy in women with Alport syndrome.
Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Cesarean Section; Female; Follow-Up Studies; G | 2013 |
2 other studies available for spironolactone and Alport Syndrome
| Article | Year |
|---|---|
Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.
Topics: Adolescent; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Child; Creatinine | 2013 |
The effect of aldosterone blockade in patients with Alport syndrome.
Topics: Adolescent; Adult; Aldosterone; Child; Female; Glomerular Filtration Rate; Humans; Male; Mineralocor | 2006 |